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AbstrAct:
The membrane-anchored matrix metalloproteinase-regulator RECK is often down-
regulated in various types of cancers; the levels of residual RECK in resected tumors 
often correlate with better prognosis. Forced expression of RECK in cancer cells 
suppresses tumor angiogenesis, invasion, and metastasis in xenograft models. 
RECK is therefore a promising marker for benignancy and a potential effector in 
cancer therapy. We established a cell line containing two transgene systems: (1) 
the secreted alkaline phosphatase (SEAP) gene fused to Reck promoter and (2) 
the HRAS12V oncogene driven by the Tet-off promoter system. This cell line exhibits 
transformed phenotype in regular medium and flat morphology with increased SEAP 
activity in the presence of doxycycline, allowing the assessment of RECK-inducing 
activity of chemicals in the contexts of both transformed and untransformed cells. 
Our pilot experiments with 880 known bioactive compounds detected 34 compounds 
that activate RECK promoter; among these, 10 were authentic anticancer drugs. 
Four selected compounds up-regulated endogenous RECK protein in several human 
cancer  cell  lines.  The  top-ranking  compound,  disulfiram,  strongly  suppressed 
spontaneous lung-metastasis of human fibrosarcoma cells in nude mice. Our data 
demonstrate the value of this screen in discovering effective cancer therapeutics.
Abbreviations used:  MMP, matrix metalloproteinase; RECK, reversion-inducing cysteine-rich protein with Kazal motifs; Dox, doxy-
cycline; SEAP, secreted alkaline phosphatase; DMSO, dimethyl sulfoxide; HPM, hypothemycin; DSF, disulfiram; DXR, doxorubicin; 
Gra, gramicidin; Pyt, pyrithione sodium salt; pDTC, pyrrolidine dithiocarbamate; GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; SEM, standard error of mean.
INtrODUctION
Despite the long-standing efforts, the number of 
effective cancer  therapeutics is  far  from  sufficient [1], 
and the problems of drug-resistance arise in many cases 
[2]. Classical anticancer drugs were screened based on 
their activities to induce shrinkage of tumor xenografts 
in experimental animals. These include several categories 
of cytotoxic drugs such as DNA-damaging agents (e.g., 
bleomycin), anti-metabolites (e.g., methotrexate), DNA-Oncotarget 2010; 1: 252-264 253 www.impactjournals.com/oncotarget
modifying agents (e.g., doxorubicin), DNA topoisomerase 
inhibitors  (e.g.,  camptothecin),  and  microtubules 
inhibitors  (e.g.,  paclitaxel).  Since  these  agents  target 
essential functions of the cells, their effective doses are 
narrow-window, and serious side-effects are unavoidable 
in many cases [1]. 
More recent approaches based on knowledge on the 
molecular bases of carcinogenesis led to the development 
of a series of agents selectively targeting oncoproteins. 
Herceptin (trastuzumab), Gleevec (imatinib), and Avastin 
(bevacizumab) are among the successful examples of such 
molecular-targeted therapeutics [3]. By definition, these 
drugs  are  effective  on  tumors  bearing  specific  genetic 
alterations; tumors initially sensitive to a drug may recur if 
second mutations convert the target oncoprotein resistant 
to the drug or if some other host mechanisms develop to 
make the cells less dependent on that particular pathway 
for their survival and/or proliferation [1]. 
Since invasion and metastasis are among the most 
problematic attributes of malignant tumors [4], inhibitors 
of  these  activities  have  also  been  sought.  The  matrix 
metalloproteinase (MMP) family is interesting in this 
regard, since some members of this large protease family 
(consisting  of  more  than  20  members)  play  important 
roles in tumor angiogenesis, invasion, and metastasis [5]. 
Although initial clinical trials with some broad-spectrum 
MMP inhibitors were discouraging, more selective MMP 
inhibitors need to be developed and evaluated under 
optimized conditions [6]. 
RECK  was  initially  identified  as  a  transformation 
suppressor  gene  inducing  flat  reversion  in  a  v-K-ras-
transformed  mouse  fibroblast  cell  line  [7,  8].  RECK 
encodes a glycosylphosphatidylinositol (GPI)-anchored 
glycoprotein of ~125 kDa, which inhibits at least four 
cancer-associated MMPs, i.e., MMP-2, MMP-7, MMP-9, 
and MT1-MMP [7, 9-11]. Although RECK is expressed 
ubiquitously in normal human organs, it is down-regulated 
in cancers of many organs including those of the lung (non-
small cell type), colorectum, breast, and pancreas [12], in 
which  the  prevalent  mechanism  is  probably  epigenetic 
silencing rather than genetic mutations [13, 14].  Clinical 
studies  also  indicate  that  the  levels  of  residual  RECK 
expression in resected tumor tissues positively correlate 
with  survival  of  the  patients  [12].  Down-regulation  of 
RECK is also found in the cells transformed by various 
oncogenes, including activated RAS  [7,  15,  16].  Such 
down-regulation is probably essential for carcinogenesis, 
since  forced  expression  of  RECK  in  cancer  cells 
suppresses tumor angiogenesis, invasion, and metastasis 
as assessed by xenograft experiments in nude mice [7, 
9]. These findings also imply that malignant behaviors of 
tumor cells may be suppressed if the dormant endogenous 
RECK in cancer cells be activated. 
In the present study, we set up an assay system for 
the discovery of small molecules that up-regulate Reck 
promoter. Our pilot study with a small chemical library 
demonstrated the value of this assay system in discovering 
new anticancer drugs including those with anti-metastasis 
activity.
rEsULts
Establishment of the screening system
Our  previous  study  indicated  that  the  4.1-kb  up-
stream fragment of mouse Reck gene contains elements 
responsible for transcriptional repression by activated 
RAS oncogenes as examined by luciferase reporter assay 
[15]. We inserted this fragment up-stream of the secreted 
alkaline phosphatase (SEAP) gene, a marker suitable 
for  high-throughput  screening. As  a  recipient  cell,  we 
chose to use a derivative of rat fibroblast cell line CREF 
engineered to express HRAS12V oncogene under the control 
of tetracycline-regulated trans-activator (Tet-off) system 
(Fig. 1A, panel 1) [15], since this regulatable oncogene 
was expected to facilitate our initial selection of indicator 
cell lines that produce more SEAP when the oncogene is 
repressed. Moreover, such a recipient cell should allow 
us to compare the effects of a compound in the context of 
transformed and non-transformed cells (Fig. 1A, panel 2). 
Thus, in our complete assay format (Fig. 1 A, panel 
3), the indicator cell line named YM3 is plated onto 96-
well  plates  in  quadruplicate,  two  in  growth  medium 
(RAS-on) and two in the medium containing doxycycline 
(Dox; RAS-off), allowed to adhere for several hours, and 
then treated with test chemicals for 48 h. A small portion 
of  culture  supernatant  was  used  for  chemiluminescent 
SEAP assay, and the remaining medium and the cells were 
used for colorimetric quantification of viable cells. This 
assay yields 4 sets of duplicate data which represent the 
effects of chemicals on the following four parameters: (i) 
the number of transformed cells, (ii) the SEAP activity 
in transformed cells, (iii) the number of non-transformed 
cells,  and  (iv)  the  SEAP  activity  in  non-transformed 
cells. In large-scale screenings, a simplified version using 
one culture condition (e.g., in the absence of Dox) can 
be employed, and then the selected compounds can be 
further evaluated using the complete format in secondary 
screening. 
Pilot study with a small chemical library
To test the utility of this assay in drug screening, we 
employed a chemical library composed of 880 structurally 
diverse  known  bioactive  compounds.  The  biological 
mechanisms or pharmacological effects of these diverse 
compounds have experimentally been verified, and more 
than 85% of the compounds have been marketed either 
in  the  United  States  or  Europe  as  pharmaceuticals  or Oncotarget 2010; 1: 252-264 www.impactjournals.com/oncotarget 254
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Figure 1: Drug screening using the reck-promoter-reporter system. (A) Schematic representation of the transgene systems 
used to establish YM3 cells (1), effects of Dox on YM3 cell (2), and outline of the YM3 assay (3). (B) A part of the results of first screening. 
Extents of SEAP-activation (relative to untreated cells) after treatment of YM3 cells with top-34 chemicals (5 µM) for 48 h in the absence (black 
bars) or presence (white bars) of Dox are shown. (C) Dose-response assays using four selected chemicals on YM3 cells. Doses of each drug are 
listed on the right table. Data with vehicle (V; 1% DMSO) or hypothemycin (HPM; 1 µg/ml) are also shown. Bar represents mean ± SEM (n = 4). 
(D) Effects of four chemicals on the Reck-luciferase promoter in HT1080 cells. HT1080 cells stably transfected with pGL3-4110 were exposed to 
either DSF, Pyt, DXR, or ammonium pyrrolidine dithiocarbamate (pDTC, a compound related to DSF) at indicated doses for 48 h, and the firefly 
luciferase activity in the cell lysate was measured and normalized per cell. Data with vehicle (V; 1% DMSO) or HPM (1 µg/ml) are also shown. 
NT, no treatment. Bar represents mean ± SEM (n = 3). Student’s t-test (vs. V): * P < 0.05, ** P < 0.001.
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supplements in a wide range of therapeutic areas. In the 
primary  screening,  151  chemicals  were  found  to  up-
regulate the expression of the SEAP reporter gene more 
than  hypothemycin  (HPM),  a  positive  control  which 
typically up-regulates the SEAP activity about two fold 
by inhibiting MEK. In most cases, the extent of SEAP up-
regulation (i.e., fold-induction) was higher in transformed 
cells than in non-transformed cells (e.g., Fig. 1B, black bar 
vs. white bar) with a few exceptions, such as chlorhexidine 
(Fig. 1B, bars 30). 
We  next  performed  dose-response  studies  with 
the 151 chemicals to validate the results of the primary 
screening and to determine their optimal concentrations 
as well as maximal activities in this assay. Thirty-four 
drugs that marked high scores (i.e., the extent of induction 
in the absence of Dox) in this secondary screening are 
listed in Table 1. These drugs can be classified into 8 
categories based on their pharmacological activities 
(Table 2). Among these, four chemicals (4/34 = 12%) are 
tetracycline analogues (Table 1, in the “Class” column), 
and they probably activate the Reck promoter by inhibiting 
HRAS12V transactivation, which is supported by the lack 
of activity in the presence of Dox (Table 1, the “Activity 
in Dox” column). These tetracycline analogues may be 
considered as a set of internal controls, and their 13-fold 
enrichment  (the  original  library  contains  8  tetracycline 
analogues: 8/880 = 0.9%) unintendedly demonstrate the 
effectiveness of this assay. 
Interestingly,  eight  of  the  34  chemicals  (8/34  = 
24%; Table 1, asterisk in the “Class” column) are those 
included  in  the  88-member  FDA-Approved  Oncology 
Drugs Set (Developmental Therapeutics Program, NCI, 
USA), representing remarkable (12-fold) enrichment of 
anticancer drugs (the original library contains 18 drugs 
included  in  the  FDA-Approved  Oncology  Drugs  Set: 
18/880 = 2%). Two other chemicals, camptothecine and 
diaziquone (Table 1, Class II with no asterisk), may also 
be classified as anticancer drugs. Hence, nearly one third 
(10/34 = 29%) of the drugs selected in this experiment 
represent classical anticancer drugs. 
Effects of selected chemicals on rEcK expression
As  materials  for  further  studies,  we  selected  top-
ranking chemicals from four different pharmacological 
classes: disulfiram (DSF; alcohol deterrent), doxorubicin 
(DXR;  anticancer  drug),  gramicidin  (Gra;  antibacterial 
agent), and pyrithione sodium salt (Pyt; antifungal agent). 
We first obtained fresh batches of these chemicals and 
confirmed  their  activities  in  two  assay  systems:  dose-
response  assay  in  YM3  cells  (Fig.  1C) and luciferase 
reporter assay in human fibrosarcoma cell line, HT1080 
(Fig. 1D). These results exclude the possibility that the 
results obtained in our pilot screening represented some 
artifacts due to the particular batches of compounds or to 
the cell line used in the screening. 
Moreover, these chemicals could up-regulate 
endogenous RECK protein in multiple human tumor cell 
lines as examined by immunoblot assay (Fig. 2), with an 
exception of Pyt, which showed little effects on RECK 
expression in RZmet3 cells under these conditions. 
Effects of DsF on tumor cells in vitro
Among the chemicals that marked high scores in this 
assay, DSF is of particular interest, since it consistently 
up-regulates  RECK  in  various  tumor  cell  lines,  down-
regulates gelatinases (see below), and is known to have  MURAI, Figure 2 
A 
B 
C 
D 
A549
HPM Gra DSF DXR V Pyt
3.4 2.7 3.3 3.8 2.0 1.0
RECK
GAPDH
SW480
3.0 6.0 6.2 2.4 2.4 1.0
HPM Gra DSF DXR V Pyt
RECK
GAPDH
Figure 2: Effects of selected drugs on rEcK pro-
tein expression in human tumor cell lines. The cells 
(density: HT1080 and A549, 5 x 104; RZmet3, 1 x 105; SW480, 
1.5 x 105 per 60-mm dish) plated on the previous day were ex-
posed to a test chemical at IC50 as determined by colony forma-
tion assay, HPM (1 µg/ml), or 1% DMSO (V) for 48 h (A, B) or 
72 h (C, D), and the cell lysates were analyzed by immunoblot 
assay using anti-RECK antibody (5B11D12; top panel) followed 
by striping and reprobing with anti-GAPDH antibody (bottom 
panel). Dosage: A and B (IC50 determined on HT1080), DSF 
78 nM, DXR 1.8 nM, Gra 3.2 nM, Pyt 250 nM, pDTC 10 µM; 
C, DSF 42 nM, DXR 2.5 nM, Gra 8.4 nM, Pyt 178 nM; D, DSF 
40 nM, DXR: 3.2 nM, Gra: 6.5 nM, Pyt: 170 nM. Relative band 
intensities, normalized against GAPDH and then divided by the 
normalized value for the cells treated with vehicle, are given at 
the bottom of each panel.Oncotarget 2010; 1: 252-264 www.impactjournals.com/oncotarget 256
MURAI, Table 1
Table 1. Top-34 chemicals selected using the YM3 assay
Rank  Chemical
1) Optimal conc. 
(μM)
2)
Induction 
(fold)
Activity in 
Dox
3) Class
4)
1 Disulfiram [DSF] 1.67 18.0 + Ⅰ
2 Pyrithione sodium salt [Pyt] 1.67 17.5 + Ⅴ
3 Thimerosal 5.00 9.33 + Ⅴ
4 Doxorubicin hydrochloride [DXR] 5.00 8.55 + Ⅱ*
5 Camptothecine (S,+) 5.00 7.71 + Ⅱ
6 Gramicidin [Gra] 5.00 7.30 + Ⅳ
7 Daunorubicin hydrochloride 1.67 6.22 + Ⅱ*
8 Cephaeline dihydrochloride heptahydrate 5.00 5.61 + Ⅶ
9 Mechlorethamine hydrochloride 5.00 4.98 + Ⅱ*
10 Emetine dihydrochloride  1.67 3.79 - Ⅶ
11 Mitoxantrone dihydrochloride 0.556 3.60 + Ⅱ*
12 Diaziquone 5.00 3.54 + Ⅱ
13 Haloprogin 5.00 3.48 + Ⅴ
14 Lycorine hydrochloride 5.00 3.44 + Ⅶ
15 Methotrexate 5.00 3.42 + Ⅱ*
16 Paclitaxel 5.00 3.32 + Ⅱ*
17 Menadione 5.00 3.21 + Ⅷ
18 Albendazole 1.67 2.89 + Ⅵ
19 Meclocycline sulfosalicylate 0.0617 2.59 - Ⅳ
¶
20 Demeclocycline hydrochloride 1.67 2.57 - Ⅳ
¶
21 Minocycline hydrochloride 0.556 2.54 - Ⅳ
¶
22 Podophyllotoxin 5.00 2.48 + Ⅷ
23 Harmine hydrochloride 5.00 2.44 + Ⅷ
24 Pyrimethamine 5.00 2.33 + Ⅲ
25 Trimeprazine tartrate 5.00 2.30 - Ⅷ
26 Cycloheximide 5.00 2.29 + Ⅳ
27 Perhexiline maleate 5.00 2.28 + Ⅷ
28 Triamterene 5.00 2.25 - Ⅷ
29 Triflupromazine hydrochloride 0.0617 2.18 - Ⅷ
30 Raloxifene hydrochloride 0.556 2.17 - Ⅱ*
31 Piperlongumine 5.00 2.06 - Ⅷ
32 Hycanthone 5.00 2.02 + Ⅵ
33 Etoposide 5.00 1.99 + Ⅱ*
34 Doxycycline hydrochloride 0.185 1.96 - Ⅳ
¶
* Included in FDA-Approved Oncology Drugs Set, Developmental Therapeutics Program, NCI
¶ Tetracycline analogue
1) Chemicals selected for detailed studies are in bold letters, with their abbreviations in the parentheses.
2) Optimal concentration determined by dose-response assays (dosages: 0.0617, 0.185, 0.556, 1.67, 
    5.00 µM) using YM3 cells.
3) Activity in the presence of Dox (i.e., HRAS    -off): +, more than 1.9-fold;  +, between 1.9 and 1.5-fold;
     -, less than 1.5-fold
4) See Table 2.
12VOncotarget 2010; 1: 252-264 www.impactjournals.com/oncotarget 257
. Antibacterial agents 
Ⅰ
Ⅰ
Ⅱ
Topo 
DNA synthesis, Topo 
MURAI, Table 2
Table 2. Properties of the top-34 chemicals
Class Chemical Target of inhibition (application)  / mode of action
. Alcohol deterrent Disulfiram [DSF] Aldehydodehydrogenase in hepatocyte, superoxide 
dismutase-1, chelation of zinc and copper cations
Ⅱ. Anticancer drugs
      Vinca alkaloid Camptothecine (S, +)
      Podophyllum alkaloid Etoposide Topo 
      Anthracyclines Doxorubicin [DXR] Ⅱ
Daunorubicin DNA synthesis, Topo Ⅱ
      Nitrogen mustard Mechlorethamine DNA synthesis, Topo Ⅱ
      DNA alkylator Diaziquone DNA synthesis
      Antibiotic Mitoxantrone DNA synthesis
      Taxane Paclitaxel Tubulin dissociation
      Hormone analogue Raloxifene Estrogen receptor
      Antimetabolite Methotrexate Dihydrofolate reductase
Ⅲ. Antimalarial agent Pyrimethamine Dihydrofolate reductase
Ⅳ
      Antibiotic peptide Gramicidin [Gra] Cell membrane, phospholipid
      Piperidone Cycloheximide Protein synthesis, ribosome
      Tetracycline analogues Demeclocycline Protein synthesis, bacterial ribosome
Doxycycline Protein synthesis, bacterial ribosome
Meclocycline Protein synthesis, bacterial ribosome
Minocycline Protein synthesis, bacterial ribosome
Ⅴ. Antifungal agents Pyrithione sodium salt [Pyt] Chelation of zinc cation
Haloprogin Damaging fungal membrane
Thimerosal Generation of ethyl-mercury
Ⅵ. Anthelmintic agents Albendazole Tubulin polymerization (antiworm)
Hycanthone DNA/RNA synthesis, parasite nervous system                 
(antischistosome)
Ⅶ. Vomiting alkaloids Cephaeline Protein synthesis
Emetine Protein synthesis
Lycorine Protein synthesis
Ⅷ. Others Menadione (Vitamin K3) ROS generation
Podophyllotoxin Tubulin polymerization                                                    
(antiwart, precursor of etoposide)
Trimeprazine (Alimemazine) Histamine receptor, muscarinic acetylcholine receptor 
Triflupromazine Dopamine receptor, muscarinic acetylcholine receptor 
Perhexiline L-type calcium channel, sodium/potassium ATPase, 
carnitine palmitoyltransferase-1
Triamterene Sodium/potassium ATPase
Harmine Monoamine oxidase A
Piperlongumine Thromboxane A2 receptor
Ⅰ ⅠOncotarget 2010; 1: 252-264 258 www.impactjournals.com/oncotarget
relatively low toxicity in vivo [17]. We therefore chose to 
mainly use this drug in our subsequent studies aiming to 
find other bioassays useful in narrowing down promising 
candidates. 
Previous studies indicate that transfection of RECK-
expression vector induces flat reversion (i.e., increased 
cell-substrate  adhesion)  in  transformed  cells  [7]  and 
suppresses cell migration in several cell types [18, 19]. 
We  therefore  examined  the  morphology  and  behavior 
of RZmet3 cells in the absence or presence of DSF by 
time-lapse video-microscopy (Fig. 3). DSF was found to 
induce flattening/spreading of these cells (Fig. 3A, B) and 
to reduce the speed in random migration (Fig. 3C). Hence, 
DSF could recapitulate some effects of RECK-transgene 
on the morphology and behavior of these sarcoma cells. 
Effects of DsF on tumor growth and metastasis
Expression  of  RECK  in  HT1080  cells  results  in 
down-regulation  of  pro-MMP-9  and  active  MMP-2 
in culture supernatant [7, 9, 20] and in suppression of 
metastatic  activity  in  nude  mice  [7].  To  facilitate  the 
evaluation of anti-tumorigenic/anti-metastatic activity of 
Reck-activating drugs in vivo, we established a luciferase-
tagged derivative of HT1080 (named RM72) that shows 
spontaneous  lung-metastasis  within  two  weeks  after 
subcutaneous  inoculation  into  nude  mice.  RM72  cells 
were found to respond to the four chemicals by increased 
RECK expression (Fig. 4A) and concomitant decreases 
in the level of pro-MMP-9 in culture supernatant (Fig. 
4B, panel 1 and 2). In addition, DSF could also lower the 
levels of pro-MMP-2 as well as intermediate and mature 
MMP-2 in culture supernatant (Fig. 4B, panels 3 and 4). 
Given these promising results in vitro,  we  then 
tested the effects of DSF on the growth and metastasis 
of RM72 cells in nude mice. In this assay, RM72 cells 
were inoculated subcutaneously into nude mice, allowed 
to grow into small tumor for 5 days, and then treated with 
DSF  dissolved  in  olive  oil  (50  mg/kg/day)  or  vehicle 
alone (control) by intraperitoneal injection for 14 days 
(Fig. 4C). Under these conditions, DSF had no significant 
effects on the volume of primary tumors (Fig. 4D, panels 
1 and 2), and yet lung-metastasis was strongly suppressed 
in the DSF-treated mice (Fig. 4D, panels 1 and 3). The 
difference is even more significant when the extent of 
metastasis is normalized against tumor volume (Fig. 4D, 
panels 4). No obvious side effect was observed during 
these experiments. 
Taken  together,  these  data  demonstrate  the  utility 
of our Reck-promoter-reporter assay using YM3 cells for 
discovering promising candidates for cancer therapeutics, 
which  include  anti-metastatic  drugs  with  low  toxicity 
as well as conventional classes of anticancer drugs. The 
RM72 cells also provide a powerful assay system that 
allows us to rapidly assessing the effects of various agents 
on tumor growth and metastasis in vivo. 
DIscUssION
RECK is down-regulated in a wide variety of tumors 
and in the cells transformation by various oncogenes [7, 
12, 15]; forced expression of RECK in tumor cells results 
in suppression of tumor proliferation, angiogenesis, 
invasion, and metastasis [7, 9]. RECK is therefore a useful 
marker for benignancy and a promising target (or effector) 
to  be  activated  in  cancer  therapy.  The  Reck-promoter-
reporter assay may detect compounds that suppress 
malignancy  via  multiple  mechanisms:  e.g.,  some  may 
suppress malignancy via activation of RECK while some 
others may suppress malignancy by other mechanisms, 
consequently up-regulating RECK. This assay therefore 
has a feature of both molecular-targeting approach and 
bioactivity-oriented  approach.  We  also  expected  that 
this assay may not detect cytotoxic drugs, since it relies 
of a positive readout (i.e., promoter activation in viable 
cells) rather than a negative one (e.g., cell killing or tumor 
shrinkage). 
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Figure 3: Effects of DsF on the morphology and 
migration of rZmet3 cells in vitro. (A) Differential 
interference contrast (DIC) images of RZmet3 cells incubated 
in the absence (V, 1% DMSO) or presence of DSF (10 µM) for 
24 h. Scale bar: 50 µm. (B) Cell spreading as assessed by the 
area occupied by individual cells on micrographs as shown in 
(A) using Image J software. The results are presented as the ra-
tio to the control cells. Bar represents mean ± SEM (n = 100). 
(C) Relative speed of random migration in the absence (V, 1% 
DMSO) or presence of 10 µM DSF. Bar represents mean + SEM 
(n = 10). Oncotarget 2010; 1: 252-264 259 www.impactjournals.com/oncotarget
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Figure 4: Effects of DsF on rM72 cells. (A) Effect of various chemicals on the level of endogenous RECK protein in RM72 cells. The 
cells (1 x 105 cells per 60-mm dish) plated on the previous day were treated with indicated drug (dosage: see legend to Fig. 2A, B) for 48 h, and 
the level of RECK protein was estimated by immunoblot assay. Relative band intensities, normalized against GAPDH and then divided by the 
value for vehicle (V; 1% DMSO), are given at the bottom. (B) Gelatin zymography with culture supernatant of RM72 cells treated with indicated 
chemicals for 48 h (1). Intensity of the bands corresponding to pro-MMP-9, pro-MMP-2, and intermediate/mature MMP-2 were estimated using 
MultiGauge software (FUJIFILM), normalized against the cell number as determined by SF assay, and presented in the separate bar graphs (2-4). 
Dosage: DSF (16 µM), DXR (210 nM), Gra (32 nM), Pyt (5 µM), HPM (1 µg/ml), or pDTC (20 µM). (C, D) Effects of DSF on the growth and 
lung metastasis of RM72 cells inoculated subcutaneously into nude mice. Nude mice bearing an RM72 tumor (diameter ~3 mm) were treated 
(intraperitoneal injection) with vehicle (V) or DSF (50 mg/kg/day) for 14 days. Bioluminescence flux from whole body (top panels) and the lungs 
(bottom panels) were recorded. Three animals from each group bearing a primary tumor of similar size are shown in (C). (D) Statistical data of 
nude mouse assays as shown in (C): (1) relationship between tumor volume and lung metastasis (relative bioluminescence intensity; each dot 
represents one animal), (2) tumor volume, (3) metastasis, (4) metastasis/tumor volume. Bar represents mean ± SEM (n = 5).  Experiments were 
repeated twice with similar results.
To  our  surprise,  however,  our  pilot  screening 
detected  “cytotoxic”  anticancer  drugs  very  efficiently. 
These  drugs  activate  Reck  promoter  while  killing  the 
cells; we also found many drugs in the library that kills 
the cells without activating Reck promoter. Hence, our 
finding may imply that RECK is a common effector for 
these  anticancer  drugs. Alternatively,  these  drugs  may 
induce a common change in the cells that leads to RECK 
up-regulation.  Nevertheless,  this  assay  must  be  useful 
in finding new compounds with anticancer activities of 
conventional types. 
Could  this  screen  be  useful  in  finding  new  types 
of  anticancer  drugs?  In  this  particular  case,  could  we 
expect anticancer activities in any of the 20 non-Class-
II  compounds  listed  in Table  1  (excluding  tetracycline 
analogues)? One may argue that the activity to up-regulate 
Reck may be just one of several properties found in 
anticancer drugs so that only a fraction of Reck-activating 
drugs (e.g., Class II) represent bona fide anticancer drugs. 
Our observations with DSF, however, argue against this 
possibility. 
DSF has been used as an anti-alcoholism drug, since 
it inhibits aldehydodehydrogenase in hepatocytes, leading 
to an acute sensitivity to alcohol [21, 22]. In recent years, 
several papers have suggested anticancer activities of 
DSF (i.e., suppression of tumor growth, invasion in vitro, 
and angiogenesis and metastasis in vivo) [17, 23-28]. Low 
toxicity in vivo distinguishes DSF from classical cytotoxic 
anticancer drugs [17]. Proposed mechanisms of its actions 
include  redox-related  apoptosis  [23],  up-regulation  of Oncotarget 2010; 1: 252-264 260 www.impactjournals.com/oncotarget
metallothionein  [28],  inhibition  of  proteasome  [26] 
or  superoxide  dismutase-1  activity  [24],  and  down-
regulation of several genes including MMP2, MMP9 [25, 
27], CYP2E1 [29], and MCM [28]. This study not only 
expands  our  knowledge  on  DSF  by  demonstrating  its 
activities to suppress spontaneous fibrosarcoma metastasis 
and to up-regulate RECK but also strengthen our notion 
that the Reck-promoter-reporter assay may be useful in 
finding new types of anticancer therapeutics, including 
agents with low toxicity in vivo and with anti-metastatic 
activity. Some other drugs selected by this assay, such as 
perhexiline, triamterene (Na+/K+-ATPase inhibitors), and 
piperlongumine  (thromboxane A2  receptor  antagonist), 
also support this prospect, since anticancer activities 
of cardiac glycosides (Na+/K+-ATPase  inhibitors)  [30] 
and  the  involvement  of  thromboxane  A2  signaling  in 
angiogenesis  and  tumor  metastasis  [31,  32]  have  been 
reported. 
The observed effects of DSF on the behaviors of 
HT1080 cells in culture (Figs. 2 and 3) are consistent with 
the model that RECK plays an important role in DSF-
mediated  metastasis  suppression.  Our  preliminary  data 
indicate  that  RECK-depletion  with  siRNA  suppresses 
DSF-mediated  pro-MMP-9  down-regulation  (data 
not  shown),  and  this  is  consistent  with  the  previous 
observation by Takagi et al. that RECK suppresses MMP9 
transcription [20]. It remains to be clarified, however, to 
what  extent  the  up-regulated  RECK  contributes  to  the 
DSF-mediated metastasis suppression in vivo. Conditional 
Reck mutant mice may be useful in addressing this issue. 
In such studies, we may also be able to test the interesting 
possibility that DSF and Reck suppress tumor metastasis 
by regulating stem cell niche [33-35]. 
Given a promising assay system that can be adapted 
to high throughput screenings, it is also important to have 
independent  and  efficient  assay  systems  for  narrowing 
down  promising  candidates.  In  this  study,  we  tested 
five  assays,  mainly  using  HT1080  fibrosarcoma  cell 
line and its derivatives: (i) luciferase reporter assay (to 
assess the effects on the Reck promoter in human cells), 
(ii)  immunoblot  assay  with  several  human  tumor  cell 
lines  (to  see  whether  endogenous  RECK  protein  can 
be up-regulated), (iii) gelatin zymography with culture 
supernatant (to assess the effects on gelatinases), (iv) time-
lapse microscopy (to assess the effects on cell morphology 
and motility), and (v) subcutaneous inoculation into nude 
mice (to assess the effects on tumor growth and metastasis). 
Among these assays, ii), iii) and v) seem to be useful for 
our purpose.  YM3 assay performed in the presence of 
Dox is also useful in classifying the candidates into two 
groups  based  on  their  dependence  on  RAS  pathway. 
Combination of two or more agents tested in one or more 
of these assays may also be useful for classifying drugs 
as well as for finding synergistic combinations of drugs. 
Although  it  was  an  obvious  option,  we  did  not 
choose  to  use  Matrigel  invasion  assay  for  narrowing 
down candidates, mainly because of its relatively high 
cost. Instead, we concentrated on establishing a reliable 
assay to monitor tumor growth and metastasis in vivo. 
The luciferase-tagged, highly metastatic cell line RM72 
is particularly useful for this purpose, since it allows us 
to detect and quantify metastases as well as tumor growth 
in living animals within a relatively short period of time, 
typically in 3 weeks. Given the prevalence of carcinomas 
among human malignancies, assays using epithelial 
or carcinoma-derived cell lines may be considered 
more appropriate. We believe, however, that the use of 
mesenchymal  cell  lines,  CREF  and  HT1080,  as  useful 
model systems in early steps of drug screening can be 
justified  in  light  of  the  widely  recognized  importance 
of epithelial-mesenchymal transition in carcinoma 
progression  [36].  Of  course,  the  efficacy  of  candidate 
drugs should also be tested in carcinoma models in later 
steps of evaluation. 
The chemicals detected by this assay may give us 
some hints on the mechanisms of Reck gene regulation. For 
instance, the list (Tables 1, 2) contains multiple compounds 
sharing common activities or properties, such as heavy-
metal chelators, DNA-replication inhibitors, microtubules 
inhibitors, dihydrofolate reductase inhibitors, and protein 
synthesis inhibitors. In fact, many of these drugs as well 
as  menadione  [37]  are  potential  generators  of  reactive 
oxygen  species  (ROS)  [38-42].  The  four  top-ranking 
drugs, however, could up-regulate RECK in SW480 which 
carries a mutant p53 gene [43] (Fig. 2D), suggesting p53-
independent nature of this response. Further studies to 
understand how these drugs activate Reck transcription 
may provide fresh insights into the mechanisms of 
transcriptional regulation, signal transduction, malignant 
transformation, and its suppression. 
MAtErIALs AND MEtHODs
Animal experiments
The experiments using mice had been approved by 
Animal Research Committee, Kyoto University, and were 
performed in accordance with MEXT Notice No. 71 and 
the Act on Welfare and Management of Animals, Japan.
cell lines and cell culture
The origins of cell lines used are as follows: CREF, 
rat embryo fibroblast [44]; HT1080, human fibrosarcoma 
[45]; A549 human lung adenocarcinoma [46]; SW480, 
human  colon  adenocarcinoma  [47].  These  cells  were 
cultured  in  growth  medium  [DMEM  (Nacalai),  10% 
fetal bovine serum (FBS), penicillin-streptomycin] under 
standard  conditions.  RZmet3,  a  derivative  of  HT1080 
carrying the neo marker and recovered from a lymph node Oncotarget 2010; 1: 252-264 261 www.impactjournals.com/oncotarget
metastasis after subcutaneous inoculation into a nude 
mouse [7], was cultured in growth medium containing 1 
mg/ml G418. 
Plasmids and transfection
A segment of mouse Reck  gene  promoter  [4.1 
kb  KpnI-HindIII  fragment  from  pGL3-4110  [15]  was 
inserted  between  the  corresponding  sites  of  pSEAP2-
Basic  (Clontech)  to  generate  pSEAP-RP4.1.  Stable 
transfection  was  performed  using  CalPhos  Mammalian 
Transfection Kit (Clontech) with purified cellular DNA as 
carrier [Ratio (carrier:plasmid; w/w) = 1:3-1:5].
Establishments of indicator cells
A derivative of CREF cell line, named TF323-C3, 
carrying the HRAS12V  oncogene under the control of a 
tetracycline-sensitive  transactivator  (Tet-off)  system 
has been described elsewhere [15]. TF323-C3 contains 
neo marker and exhibits transformed morphology in 
growth medium and flat morphology in the presence of 
doxycycline (Dox; 2 µg/ml). TF323-C3 cells were co-
transfected  with  pSEAP-RP4.1  mixed  with  pUCSV-
BSD [ratio (w/w) = 4:1] followed by selection in growth 
medium containing 8 µg/ml blasticidine-S. A clone (named 
YM3) that showed highest degree of SEAP up-regulation 
(see  below  for  SEAP  assay)  after  Dox-treatment  was 
selected. SEAP was also up-regulated in YM3 cells after 
treatment with hypothemycin (1 µg/ml), a MEK inhibitor 
inducing flat reversion in v-K-ras-transformed cells [48, 
49]. To establish an indicator cell line for assessing anti-
tumorigenic and anit-metastatic activities of a drug in vivo, 
RZmet3 cells were co-transfected with pGL4 (contaning 
Photinus pyralis luciferase gene; Promega) mixed with 
pcDNA3.1(-)-Hygro (Invitrogen), followed by selection 
in growth medium containing hygromycin-B (400 U/ml). 
Two  clones  stably  expressing  high  levels  of  luciferase 
were  isolated  and  inoculated  subcutaneously  into  nude 
mice. After 4 weeks, metastatic foci were resected from 
their lungs, dissociated, and cultured in growth medium 
containing G418 and hygromycin-B. After re-cloning in 
culture, one clone retaining high luciferase activity as well 
as lung-metastatic activity was isolated and named RM72. 
chemicals
The  880-member  Prestwick  Chemical  Library 
(Prestwick Chemical, Illkirch, France) dissolved in nano-
pure grade dimethyl sulfoxide (DMSO; Wako) was used 
for initial screening. Independent batches of disulfiram, 
doxorubicin, gramicidin, pyrithione sodium salt, and 
ammonium  pyrrolidine  dithiocarbamate  were  obtained 
from Sigma. Hypothemycin was a kind gift from Shionogi 
& Co. Ltd.
sEAP assay and luciferase assay
YM3  cells seeded onto 96-well plates at 1  x  104 
cells in 100 µl growth medium per well were incubated 
for  5  h  to  allow  the  cells  to  settle. The  drug  solution 
(500 µM, 1 µl) was added to the medium, and the plates 
were  incubated  for  additional  48  h. A  portion  (10  µl) 
of culture supernatant was sampled, incubated at 65 °C 
for 30 min, and then subjected to the SEAP assay using 
Great  EscAPeTM  SEAP  Chemiluminescence  Detection 
Kit (Takara Bio). The remaining medium and the cells 
were  subjected  to  the  cell-counting  assay  using  SF 
reagent (Nacalai): i.e., SF reagent (10 µl per well) was 
added to the medium, the plates were incubated for 3 h 
in a CO2-incubator, and the absorbance at 450 nm (A450) 
was measured. The SEAP chemiluminescence count was 
divided by the A450 value to obtain SEAP activity (per 
cell), which was further divided by SEAP activity of the 
cells treated with vehicle (1% DMSO) to obtain relative 
SEAP  activity.  The  primary  and  the  secondary  (dose-
response) screenings were performed in duplicate, and the 
validation study (with new batches of compounds) was 
performed in quadruplicate. For luciferase reporter assay, 
HT1080 cells stably transfected with pGL3-4110 [15] or 
pGL3-Basic (Promega) were plated onto 96-well plate (5 
x 104/well in 100 µl growth medium), incubated for 24 
h, and 1 µl chemical solution (100-fold concentrate) or 
vehicle (DMSO) was added per well. After incubation for 
48 h, the cells were lysed and subjected to luciferase assay 
using Steady-Glo Luciferase Assay Kit (Promega). 
Immunoblot assay
The cells were lysed as  described previously [9], 
and the protein concentration was determined using DC 
protein assay kit (BIO-RAD). Proteins separated by SDS-
PAGE (10% acrylamide) were subjected to immunoblot 
assay using the mouse monoclonal anti-RECK antibody 
(5B11D12),  followed  by  re-probing  with  anti-GAPDH 
antibody (6C5, Ambion). For visualization, the Enhanced 
Chemiluminescence  kit  (Millipore)  was  used  with 
HRP-conjugated  anti-mouse  IgG-F  (ab’)2 monoclonal 
antibody (Cell Signaling) as a secondary antibody. Images 
were  recorded  and  analyzed  using  LAS-3000  and  the 
MultiGauge software (FUJIFILM). 
Motility assay
RZmet3 cells (2 x 104) seeded onto a 35-mm glass-
base dish (IWAKI) were incubated for 24 h, and the medium 
was replaced with growth medium containing 1% DMSO Oncotarget 2010; 1: 252-264 262 www.impactjournals.com/oncotarget
(vehicle) or 10 µM disulfiram. After incubation for 24 h, 
the medium was replaced to Leibovitz’s L-15 (GIBCO) 
containing 10% FBS and 1% DMSO or 10 µM disulfiram. 
Cell movement was recorded by time-lapse microscopy 
for 3 h (3-min interval) as described elsewhere [19]. The 
speed of migration was calculated from a time series of 
coordinates (reference point: center of the nucleus) using 
Dunn’s formula [50]. Statistical significance was assessed 
by Student’s t-test. 
Gelatin zymography
Cells (2 x 104/well) seeded onto 96-well plates and 
incubated for 24 h were exposed to fresh growth medium 
with or without various drugs or 1% DMSO (vehicle). 
After incubation for 48 h, medium was replaced to 100 µl 
DMEM containing 0.1% FBS and incubated for additional 
12 h. The culture supernatant was harvested, cleared by 
centrifugation, and analyzed by gelatin zymography as 
described previously [7]. Band intensity was normalized 
against the cell number determined by SF assay. 
tumor imaging in vivo
Mice were anesthetized and injected intraperitoneally 
with  75  mg/kg  of  d-luciferin  (Promega)  in  PBS(-). 
Bioluminescence  images  were  acquired  with  the  IVIS 
Imaging System (Xenogen) at 5 min after injection [51, 
52]. Photons emitted from living mice or from isolated 
organs were collected and integrated for a period of 60 
seconds. Images were analyzed using the Living Image 
software (Xenogen). 
Human fibrosarcoma therapy model in nude mice
For spontaneous metastasis assays, RM72 cells (3 x 
106) suspended in 0.1 ml PBS were injected subcutaneously 
into the right posterior flank of Balb/c nude mice (6 week 
old,  male,  Charles  River).  Small  tumors  (~3  x  3-mm 
diameter) developed 5 days after injection. The mice were 
randomly divided into two groups (n = 5 per group) and 
treated with DSF (50 mg/kg/day) dissolved in olive oil or 
olive oil alone (vehicle) via intraperitoneal injection using 
24-gauge needles. After 14-d treatment, the mice were 
anesthetized,  and  their  bioluminescence  was  recorded 
as described above. After the whole-body recording, the 
lungs were resected, washed with PBS (-), and subjected 
to bioluminescence recording. The tumor size (length x 
width x height) was measured once a week. Statistical 
significance was assessed by Student’s t-test. 
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